Top Research Reports for Berkshire Hathaway, Exxon Mobil & Novo Nordisk

Zacks12-07

Friday, December 6, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489263231?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/k1h7Nf7YKXEJVG0fEMqg6A--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d9b3f7b5ae7f67e58a203af36b3a7698","is_english":true,"pubTime":"2024-12-07 02:50","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2489263231","market":"us","top_or_hot":-1,"title":"Top Research Reports for Berkshire Hathaway, Exxon Mobil & Novo Nordisk","media":"Zacks","content":"<div>\n<p>Friday, December 6, 2024\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire ...</p>\n\n<a href=\"https://finance.yahoo.com/news/top-research-reports-berkshire-hathaway-185000660.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Research Reports for Berkshire Hathaway, Exxon Mobil & Novo Nordisk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Research Reports for Berkshire Hathaway, Exxon Mobil & Novo Nordisk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-07 02:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/top-research-reports-berkshire-hathaway-185000660.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Friday, December 6, 2024\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire ...</p>\n\n<a href=\"https://finance.yahoo.com/news/top-research-reports-berkshire-hathaway-185000660.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://finance.yahoo.com/news/top-research-reports-berkshire-hathaway-185000660.html","article_id":"2489263231","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/k1h7Nf7YKXEJVG0fEMqg6A--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d9b3f7b5ae7f67e58a203af36b3a7698"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489263231","pubTimestamp":1733511000,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Berkshire Hathawayshares have outperformed the Zacks Finance sector  as well as the S&P 500 index  in the year-to-date period. The Zacks analyst believes that continued insurance business growth fuels float gains and driving earnings. The non-insurance businesses have also been doing well in the last few years. The addition of Pilot Travel Centers has strengthened its energy business. A sturdy capital level provides further impetus.However, exposure to cat loss induces earnings volatility and also affects underwriting results. Huge capital expenditure remains a headwind. The company is yet to come out of the shadow of Charles Munger’s passing.However, GLP-1 medicines are performing well, fueled by increasing demand. Label expansions of the same in cardiovascular and other indications will likely boost sales.Universal Health’s shares have underperformed the Zacks REIT and Equity Trust – Other industry over the past year . The Zacks analyst believes that high leverage and rising interest","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德","DD":"杜邦","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","DAL":"达美航空","AMAT":"应用材料","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","SG9999002521.SGD":"United Global Resources A Acc SGD","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","EXR":"Extra Space Storage Inc","COMM":"CommScope Holding Company Inc.","LU0654597011.USD":"BGF NATURAL RESOURCES \"A4G\" (USD) INC","CRWD":"CrowdStrike Holdings, Inc.","CTRA":"Coterra Energy Inc.","BK4500":"航空公司","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","LU0456854461.SGD":"JPMorgan Funds - Global Natural Resources A (acc) SGD","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","UHT":"Universal Health Realty Income T","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BRK.A":"伯克希尔","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","BRK.B":"伯克希尔B","IE00B3CCJ963.GBP":"GUINNESS GLOBAL ENERGY \"C\" (GBP) ACC","LU1815336760.USD":"THREADNEEDLE (LUX) GLOBAL TECHNOLOGY \"AUP\" (USD) INC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","IE00BGHQF524.EUR":"GUINNESS GLOBAL ENERGY \"C\" (EUR) ACC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","TEF":"西班牙电信","EME":"埃姆科","XOM":"埃克森美孚","LU0444973449.USD":"CT (LUX) I GLOBAL TECHNOLOGY \"DU\" (USD) ACC","LU0345781412.USD":"NINETY ONE GSF GLOBAL NATURAL RESOURCES \"A\" (USD) INC","BK4585":"ETF&股票定投概念","BK4592":"伊斯兰概念","RMD":"瑞思迈","CSIQ":"阿特斯太阳能","LU1823568750.SGD":"Fidelity Global Technology A-ACC SGD","AGS":"Playags Inc.","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","BK4225":"医疗保健房地产信托","LU2272731600.USD":"Allianz Global Intelligent Cities AM Dis USD","NSP":"Insperity"},"translate_title":"伯克希尔哈撒韦公司、埃克森美孚公司和诺和诺德公司的热门研究报告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMAT":1,"XOM":1,"UHT":1,"TEF":1,"RMD":1,"NVO":1,"NSP":1,"EXR":1,"EME":1,"DD":1,"DAL":1,"CSIQ":1,"AGS":1,"BRK.A":1,"BRK.B":1,"CTRA":1,"COMM":1,"CRWD":1},"content_text":"Friday, December 6, 2024\nThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Exxon Mobil Corporation (XOM) and Novo Nordisk A/S (NVO), as well as a micro-cap stock, Universal Health Realty Income Trust (UHT). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>\nBerkshire Hathaway shares have outperformed the Zacks Finance sector (+31.7% vs. +23.4%) as well as the S&P 500 index (+31.7% vs. +27.5%) in the year-to-date period. The Zacks analyst believes that continued insurance business growth fuels float gains and driving earnings. The non-insurance businesses have also been doing well in the last few years. The addition of Pilot Travel Centers has strengthened its energy business. A sturdy capital level provides further impetus.\nHowever, exposure to cat loss induces earnings volatility and also affects underwriting results. Huge capital expenditure remains a headwind. The company is yet to come out of the shadow of Charles Munger’s passing.\n(You can read the full research report on Berkshire Hathaway here >>>)\nExxon Mobil shares have outperformed the Zacks Oil and Gas – Integrated - International industry over the past year (+16.7% vs. +8.8%). The Zacks analyst believes that the acquisition of Pioneer and Guyana ramp-up have enhanced Exxon Mobil’s profitability. Expansion in low-carbon tech, including Baytown's hydrogen facility, positions it for future growth.\nYet, refining margins are pressured due to global capacity increases, with crack spreads softening. Regulatory hurdles in California and XOM’s reliance on finding recoverable reserves add risk.\n(You can read the full research report on Exxon Mobil here >>>)\nShares of Novo Nordisk have underperformed the Zacks  Large Cap Pharmaceuticals industry over the last six months (-23.8% vs. -9.2%). Per the Zacks analyst, the company has faced several setbacks recently. Its insulin icodec in the United States received the FDA’s CRL. A late-stage study on ocedurenone to treat patients with uncontrolled hypertension and CKD had also failed earlier. Moreover, NVO faced allegations from U.S. Senator Bernie Sanders for charging high prices for its semaglutide drugs, Ozempic and Wegovy.\nHowever, GLP-1 medicines are performing well, fueled by increasing demand. Label expansions of the same in cardiovascular and other indications will likely boost sales.\n(You can read the full research report on Novo Nordisk here >>>)\nUniversal Health’s shares have underperformed the Zacks REIT and Equity Trust – Other  industry over the past year (-4.1% vs. +10.5%). The Zacks analyst believes that high leverage and rising interest costs are an issue for the company. Dependence on Universal Health Services and flat lease growth signal limited upside potential. Vacant properties and competitive pressures are other challenges.\nYet, Universal Health Realty exhibits stable growth with lease revenues leading the way. Its healthcare-focused portfolio benefits from long-term triple-net leases. Strategic MOB expansions like Sierra Medical Plaza leverage strong healthcare demand.\n(You can read the full research report on Universal Health here >>>)\nOther noteworthy reports we are featuring today include Applied Materials, Inc. (AMAT), CrowdStrike Holdings, Inc. (CRWD) and Delta Air Lines, Inc. (DAL).Director of ResearchSheraz MianNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>\nToday's Must Read\nSolid Insurance Business Aid Berkshire (BRK.B), Cat loss Ail\nGLP-1 Drugs Boost Novo Nordisk (NVO), Market Rivalry a Woe\nExxonMobil's (XOM) Starbroek & Permian Oil Discoveries Aid\nFeatured Reports\nApplied Materials (AMAT) Rides on Strength in AGS SegmentPer the Zacks analyst, solid adoption of 200-mm systems and strengthening subscription business are benefiting the Applied Materials' Applied Global Services (AGS) segment.\nCrowdStrike (CRWD) Rides on Product Strength, AcquisitionsPer the Zacks analyst, CrowdStrike is gaining from solid contributions of its growth-oriented products, primarily Falcon platform. Also, strategic buyouts like Bionic and Reposify are positive.\nPermian Acquisition to Boost Coterra (CTRA) ProfitabilityThe Zacks analyst believes that Coterra Energy's $3.95 billion acquisition strengthens its position in the lucrative Permian Basin but is worried over lower natural gas prices.\nDuPont (DD) Benefits from Productivity Action, New ProductsPer the Zacks analyst, DuPont's cost and productivity improvement actions will support its margins. It should also gain from new product launches in high-growth markets.\nBuyouts Drive Extra Space (EXR), Low New Customer Rates AilPer the Zacks analyst, its high brand value, geographically diversified portfolio and accretive buyouts are likely to aid Extra Space Storage's performance despite lower new customer rates.\nRobust 5G Coverage Aid Telefonica (TEF) Amid Forex HeadwindsPer the Zacks analyst, Telefonica's broadened 5G footprint across Spain, Germany and Brazil is strengthening its position. Unfavorable forex trends and global macroeconomic uncertainty are concerning.\nAir Travel Demand Aids Delta Air Lines (DAL) Amid Cost WoesThe Zacks analyst is impressed by the rosy air travel demand scenario. However, the company's high labor costs are a concern.\nNew Upgrades\nSolid Pipeline, Cash Position to Aid Canadian Solar (CSIQ)Per the Zacks analyst, a strong project pipeline boosts revenue growth prospects for Canadian Solar. Also, its solid financial position should attract more investors to buy this stock\nRobust SaaS Portfolio, Mask Sales Aid ResMed (RMD)The Zacks Analyst is impressed with ResMed's Software-as-a-Service arm gaining from the MEDIFOX DAN acquisition, as well as the Brightree and MatrixCare portfolio. Mask Sales grow on new launches.\nRobust Construction Activity & Acquisitions Aid EMCOR (EME)Per the Zacks analyst, EMCOR benefits from innovation and high-demand projects, particularly in data centers, semiconductor plants, and institutional sectors. Also, focus on acquisitions bode well.\nNew Downgrades\nTechnology & Product Investment Costs Hurt Insperity (NSP)Per the Zacks analyst, Insperity's investments toward technology, product and service offerings is likely to keep the bottom line under pressure.\nLower Sales on Macro Woes Continue to Hurt CommScope (COMM)Per the Zacks Analyst, lower net sales across segments are hurting CommScope's (COMM) revenue growth. Macroeconomic woes remain a concern.\nGuess? (GES) Troubled by Challenges in Asia & North AmericaPer the Zacks analyst, weak consumer demand and traffic in North America and Asia are weighing on Guess?'s performance. Management lowered its fiscal 2025 view as it expects these hurdles to persist.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nExxon Mobil Corporation (XOM) : Free Stock Analysis Report\nDelta Air Lines, Inc. (DAL) : Free Stock Analysis Report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nBerkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report\nApplied Materials, Inc. (AMAT) : Free Stock Analysis Report\nCrowdStrike (CRWD) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489263231"}